Tirzepatide Brand Names: Mounjaro and Zepbound Explained

What Is Tirzepatide? The Molecule Behind Both Brand Names

Tirzepatide is the non-proprietary (generic) name for a peptide drug developed by Eli Lilly and assigned the internal research code LY3298176. It is the first-in-class dual receptor agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). One molecule, two receptor targets, a once-weekly subcutaneous injection.

The FDA has approved this molecule under two separate New Drug Applications, each tied to a distinct medical indication. That is why the same drug sits on pharmacy shelves under two different brand names. Here is the quick reference:

Source: FDA press announcements, NDA 215866 and NDA 217806.

Tirzepatide (LY3298176) is the shared molecule. Mounjaro and Zepbound are two FDA brand identities for the same compound under different indications.

Mounjaro: The Tirzepatide Brand Name for Diabetes

Mounjaro is Eli Lilly's brand name for tirzepatide when prescribed for type 2 diabetes in adults. The FDA approved Mounjaro on May 13, 2022 under NDA 215866 as an adjunct to diet and exercise for glycemic control. It was the first dual GIP/GLP-1 receptor agonist on the US market, and the original tirzepatide brand name.

Mounjaro ships as the single-dose KwikPen autoinjector at six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The standard titration starts at 2.5 mg weekly and steps up by 2.5 mg every four weeks as tolerated, up to a 15 mg maintenance ceiling. For the full week-by-week schedule, see our tirzepatide dosing guide.

What Does "Mounjaro" Mean?

The brand name evokes Mount Kilimanjaro, the tallest peak in Africa. Lilly has used summit imagery in Mounjaro marketing to convey reaching the top of blood-sugar control. The name is constructed, not a real word, but the mountain reference is what Lilly was going for. The "Moun" in Mounjaro is the recognizable hook.

Who Gets Prescribed Mounjaro?

Adults with type 2 diabetes. The Mounjaro label is glycemic control, not weight loss. Patients typically already carry a T2D diagnosis and may be on metformin or other oral agents. Even though Mounjaro produces real weight loss in trials, prescribing it primarily for weight loss is off-label. The FDA-approved tirzepatide brand for weight management is Zepbound. For the deep dive on the diabetes indication, see our Mounjaro guide.

Zepbound: The Tirzepatide Brand Name for Weight Management

Zepbound is the Eli Lilly brand name for tirzepatide when prescribed for chronic weight management. The FDA approved Zepbound on November 8, 2023 under NDA 217806 for adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity. It is the second tirzepatide brand to reach the market, eighteen months after Mounjaro.

A second FDA approval followed on December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. That made Zepbound the first prescription medication approved for OSA tied to obesity. Mounjaro does not carry the OSA indication, even though it is the same molecule.

What Does "Zepbound" Mean?

The "Zep" syllable links back to tirzepatide itself, drawn from the middle of the generic name. The "Bound" suffix is harder to pin down but reads as movement, momentum, or a leap forward. Like Mounjaro, the name is constructed rather than borrowed from any existing word. The point is a short, distinctive identity that keeps the weight-loss brand separate from the diabetes brand.

Who Gets Prescribed Zepbound?

Adults with obesity or overweight plus a weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or cardiovascular disease. Since the December 2024 update, adults with moderate-to-severe OSA and obesity are also on the label. Zepbound is not approved for diabetes as a primary indication; if a patient's main reason for treatment is glycemic control, Mounjaro is the labeled brand. See our Zepbound cost guide for current pricing.

Zepbound Formulations: KwikPen and Vial

Zepbound is available in two formats. The standard KwikPen single-dose autoinjector (matching Mounjaro). And single-dose vials, originally launched through LillyDirect at lower price points to compete with the compounded-tirzepatide market. Both formats contain the same active ingredient at the same dose strengths. Mounjaro is sold as KwikPen only, with no vial version. For format details, see the LillyDirect Zepbound guide.

Why Does One Molecule Have Two Brand Names?

This is the question most searchers actually want answered. The molecule is the same. The chemistry is the same. The pen is the same. So why bother with two boxes?

A few reasons, all of which reinforce each other:

• FDA regulatory structure. Each indication needs its own New Drug Application. Mounjaro's NDA 215866 covers type 2 diabetes. Zepbound's NDA 217806 covers chronic weight management. Two NDAs, two approved labels, two distinct trade names is the standard pharmaceutical convention.
• Insurance formulary separation. Commercial plans typically have one formulary for antidiabetic drugs and a separate one (often more restrictive) for anti-obesity medications. Separate brand names let payers and pharmacy benefit managers route the molecule to the correct formulary cleanly. A plan that covers Mounjaro for diabetes may not cover Zepbound for weight loss, and the reverse holds too.
• Prescriber and patient signal. Endocrinologists writing for T2D and obesity-medicine specialists writing for weight management are largely separate audiences. Distinct brand identities reduce off-label confusion, give Lilly two sets of marketing channels, and keep the diabetes franchise from getting tangled up with anti-obesity controversy.

This is not unique to Lilly. Novo Nordisk runs the same playbook with semaglutide: Ozempic for type 2 diabetes, Wegovy for chronic weight management. Same molecule, two brand names, two NDAs. See our tirzepatide vs semaglutide breakdown for the cross-class comparison.

Is the Molecule Truly Identical?

Yes. Mounjaro and Zepbound contain the same active ingredient (tirzepatide, LY3298176), produced by the same manufacturer (Eli Lilly), at the same six dose strengths (2.5, 5, 7.5, 10, 12.5, and 15 mg), administered as the same once-weekly subcutaneous injection, with the same half-life of approximately 5 days and the same dual GIP/GLP-1 agonist mechanism. The chemistry, the device (for the KwikPen form), and the pharmacokinetics are interchangeable. What differs is the printed label, the FDA-approved indication on that label, and how insurance pays for it.

FDA approval timeline for tirzepatide: Mounjaro (May 2022, diabetes), Zepbound (November 2023, weight management), and the Zepbound OSA expansion (December 2024).

International Brand Names for Tirzepatide

The Mounjaro and Zepbound brand split is largely a US phenomenon. Outside the United States, Eli Lilly generally markets tirzepatide as Mounjaro for both type 2 diabetes and chronic weight management. The European Medicines Agency, UK MHRA, Health Canada, and Japan PMDA have all authorized tirzepatide, and the brand used in those regions is Mounjaro across indications.

So if you see "Zepbound" referenced, the conversation is almost certainly about the US market. International patients on tirzepatide for weight management will see "Mounjaro" on the box. The active ingredient is identical regardless of brand or region.

Mounjaro and Zepbound: What Actually Differs

For the brand-name question, only three things matter:

• The FDA-approved indication. Mounjaro = type 2 diabetes. Zepbound = chronic weight management plus obstructive sleep apnea.
• Insurance coverage. Plans route the brand through different formulary tiers depending on diagnosis. Diabetes coverage typically broader than anti-obesity coverage.
• Available formats. Mounjaro ships as KwikPen only. Zepbound is available as both KwikPen and single-dose vial.

Everything else (chemistry, dose, schedule, half-life, side effects, contraindications) is identical. For the full feature-by-feature breakdown, read the full Mounjaro vs Zepbound comparison.